---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-043809"
form_type: "8-K"
ticker: "AURA"
cik: "0001501796"
company_name: "Aura Biosciences, Inc."
filed_at: "2025-03-24T23:59:59+00:00"
generated_at: "2026-05-24T06:30:03.799964+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Aura Biosciences Q4/FY2024 results: net loss $86.9M, cash $151.1M, Phase 3 CoMpass actively enrolling

## Summary
- Net loss $86.9M in FY2024 vs $76.4M in FY2023; R&D expenses $73.3M.
- Cash $151.1M as of Dec 31, 2024; runway into 2H 2026.
- Phase 3 CoMpass trial actively enrolling; >175 patients pre-screened globally since June 2024.
- Phase 2 trial in choroidal metastases initiated; initial data expected 2025.
- Phase 1 NMIBC data showed clinical complete responses; Tony Gibney appointed Senior Finance and Strategy Advisor.

## SEC filing metadata
- accession: 0000950170-25-043809
- form_type: 8-K
- ticker: AURA
- cik: 0001501796
- company_name: Aura Biosciences, Inc.
- filed_at: 2025-03-24T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1501796/000095017025043809/0000950170-25-043809-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1501796/000095017025043809/aura-20250324.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-043809
- JSON: https://secwatch.observer/filing/0000950170-25-043809.json
- Plain text: https://secwatch.observer/filing/0000950170-25-043809.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.